This inventor holds 2 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 1 EPO patent. Top assignees: Deutsches Krebsforschungszentrum, Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts. Active years: 2021-2025.
Company Filing History:
1 out of 159 
1 out of 166 
Years Active: 2021-2025
Title: Veronika Frehtman: Innovator in Parvovirus Research
Introduction
Veronika Frehtman is a prominent inventor based in Heidelberg, Germany. She has made significant contributions to the field of virology, particularly in the production and purification of parvoviruses. With a total of 2 patents, her work is paving the way for advancements in clinical applications.
Latest Patents
Frehtman's latest patents include innovative processes that enhance the production of H-1 parvovirus. The first patent, titled "Optimized parvovirus H-1 production," presents a robust single clone Master Cell Bank (MCB) designed for optimized production of H-1 parvovirus. This invention significantly increases infectious parvovirus production compared to the standard producer NB-324K mixed cells. The second patent, "Scalable process for oncolytic rat parvovirus H-1 production and purification based on isoelectric point-based elimination of empty particles," outlines a reproducible and effective method for purifying infectious parvovirus H-1 particles. This purification process allows for the separation of empty particles from those containing a full genome, making it compatible with large-scale H-1PV production for clinical applications.
Career Highlights
Frehtman has worked with esteemed organizations such as the German Cancer Research Center (Deutsches Krebsforschungszentrum) and the German Cancer Research Center Foundation of Public Law (Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts). Her work in these institutions has been instrumental in advancing cancer research and treatment methodologies.
Collaborations
Throughout her career, Frehtman has collaborated with notable colleagues, including Barbara Leuchs and Jean Rommelaere. These partnerships have further enriched her research and contributed to her innovative projects.
Conclusion
Veronika Frehtman is a trailblazer in the field of parvovirus research, with her patents reflecting her commitment to advancing medical science. Her contributions are vital for future developments in virology and cancer treatment.